Literature DB >> 22471861

Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics.

Thomas J Montine1, Joshua A Sonnen, Kathleen S Montine, Paul K Crane, Eric B Larson.   

Abstract

The Adult Changes in Thought (ACT) study is a longitudinal population-based prospective cohort study of brain aging and incident dementia in the Seattle metropolitan area. Observational studies using autopsies from ACT indicate that dementia is a convergent syndrome that commonly derives from Alzheimer's disease (AD), microvascular brain injury (mVBI), and Lewy body disease (LBD), and that these diseases have prevalent subclinical forms that also are commonly co-morbid. The existence of subclinical diseases highlights potential opportunities to intervene before the development of clinically apparent impairments. Our observations suggest that some such interventions already may exist to suppress processes of AD (statin therapy) or mVBI (treatment of hypertension). Reduced burden of LBD is associated with cigarette smoking; although smoking is not recommended as an intervention, these exposure data may provide clues to alternative neuroprotective mechanisms. Self reported anti-oxidant supplementation was without apparent effect in this cohort on indices of AD, mVBI, or LBD. Continued observational studies of brain aging will provide further insight into the convergent complexity of the dementia syndrome and its subclinical forms as well as highlight potential interventions that will require validation in clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22471861      PMCID: PMC3409333          DOI: 10.2174/156720512801322555

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  47 in total

Review 1.  Dementia with Lewy bodies.

Authors:  James B Leverenz; Ian G McKeith
Journal:  Med Clin North Am       Date:  2002-05       Impact factor: 5.456

2.  Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA).

Authors:  Richard J O'Brien; Susan M Resnick; Alan B Zonderman; Luigi Ferrucci; Barbara J Crain; Olga Pletnikova; Gay Rudow; Diego Iacono; Miguel A Riudavets; Ira Driscoll; Donald L Price; Lee J Martin; Juan C Troncoso
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

3.  Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.

Authors:  Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

4.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

Authors:  Kenneth Rockwood; Susan Kirkland; David B Hogan; Chris MacKnight; Heather Merry; René Verreault; Christina Wolfson; Ian McDowell
Journal:  Arch Neurol       Date:  2002-02

5.  Dementia and Alzheimer disease incidence: a prospective cohort study.

Authors:  Walter A Kukull; Roger Higdon; James D Bowen; Wayne C McCormick; Linda Teri; Gerard D Schellenberg; Gerald van Belle; Lance Jolley; Eric B Larson
Journal:  Arch Neurol       Date:  2002-11

6.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

7.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Authors:  B Wolozin; W Kellman; P Ruosseau; G G Celesia; G Siegel
Journal:  Arch Neurol       Date:  2000-10

8.  Serum lipoprotein levels, statin use, and cognitive function in older women.

Authors:  Kristine Yaffe; Elizabeth Barrett-Connor; Feng Lin; Deborah Grady
Journal:  Arch Neurol       Date:  2002-03

9.  Neuropathology of cognitively normal elderly.

Authors:  D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  27 in total

1.  Ecology of the aging human brain.

Authors:  Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine
Journal:  Arch Neurol       Date:  2011-08

Review 2.  Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Authors:  Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

3.  Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Authors:  Ge Li; Steven P Millard; Elaine R Peskind; Jing Zhang; Chang-En Yu; James B Leverenz; Cynthia Mayer; Jane S Shofer; Murray A Raskind; Joseph F Quinn; Douglas R Galasko; Thomas J Montine
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

4.  Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease.

Authors:  Cecilia S Lee; Eric B Larson; Laura E Gibbons; Aaron Y Lee; Susan M McCurry; James D Bowen; Wayne C McCormick; Paul K Crane
Journal:  Alzheimers Dement       Date:  2018-08-08       Impact factor: 21.566

5.  Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4.

Authors:  Nadia Postupna; Caitlin S Latimer; Eric B Larson; Emily Sherfield; Julie Paladin; Carol A Shively; Matthew J Jorgensen; Rachel N Andrews; Jay R Kaplan; Paul K Crane; Kathleen S Montine; Suzanne Craft; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2017-02-16       Impact factor: 4.307

6.  Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample.

Authors:  Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull
Journal:  Alzheimers Dement       Date:  2016-11-19       Impact factor: 21.566

7.  Longitudinal epidemiologic clinical-pathologic studies of aging and Alzheimer's disease.

Authors:  David A Bennett; Lenore J Launer
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

8.  White matter lesions defined by diffusion tensor imaging in older adults.

Authors:  Stephen A Back; Christopher D Kroenke; Larry S Sherman; Gus Lawrence; Xi Gong; Erin N Taber; Joshua A Sonnen; Eric B Larson; Thomas J Montine
Journal:  Ann Neurol       Date:  2011-09       Impact factor: 10.422

9.  Mild to moderate Alzheimer dementia with insufficient neuropathological changes.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Deborah Blacker; Teresa Gómez-Isla; Rebecca A Betensky; John H Growdon; Keith A Johnson; Matthew P Frosch; Reisa A Sperling; Bradley T Hyman
Journal:  Ann Neurol       Date:  2014-04-08       Impact factor: 10.422

10.  Quantitative cerebrovascular pathology in a community-based cohort of older adults.

Authors:  Swati Rane; Natalie Koh; Peter Boord; Tara Madhyastha; Mary K Askren; Suman Jayadev; Brenna Cholerton; Eric Larson; Thomas J Grabowski
Journal:  Neurobiol Aging       Date:  2018-01-31       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.